Endothelin system in oral squamous carcinoma cells: Specific siRNA targeting of ECE-1 blocks cell proliferation

International Journal of Cancer

Volumn 118, Issue 7, 2006, Pages 1645-1652

  Awano, Shuji ^a,b   Dawson, Louise A ^a   Hunter, Alison R ^a   Turner, Anthony J ^a   Usmani, Badar A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Apoptosis; Cell proliferation; ECE 1; ET receptor; ET 1; SCC; siRNA

Indexed keywords

4 CHLORO N [[(4 CYANO 3 METHYL 1 PHENYL 1H PYRAZOL 5 YL)AMINO]CARBONYL]BENZENE SULFONAMIDE MONOSODIUM SALT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME 1A; ENDOTHELIN CONVERTING ENZYME 1B; ENDOTHELIN CONVERTING ENZYME 1C; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ISOENZYME; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SMALL INTERFERING RNA; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; ECE 1 GENE; ENZYME INHIBITION; GENE; HUMAN; HUMAN CELL; KERATINOCYTE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA;

ASPARTIC ENDOPEPTIDASES; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; ENDOTHELIN-1; HUMANS; METALLOENDOPEPTIDASES; MOUTH NEOPLASMS; PROTEIN ISOFORMS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 33644862941     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21525     Document Type: Article

References (55)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332: 411-5.
2. Douglas SA. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci 1997;18:408-12.
3. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998;16:1081-98.
4. Goldie RG, Henry PJ. Endothelins and asthma. Life Sci 1999;65:1-15.
5. Corder R, Khan N, Harrison VJ. A simple method for isolating human endothelin converting enzyme free from contamination by neutral endopeptidase 24.11. Biochem Biophys Res Commun 1995;207:355-62.
6. Harrison VJ, Barnes K, Turner AJ, Wood E, Corder R, Vane JR. Identification of endothelin-1 and big endothelin-1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc Natl Acad Sci USA 1995;92:6344-8.
7. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 1999;55:902-9.
8. Shimada K, Takahashi M, Ikeda M, Tanzawa K. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett 1995;371:140-4.
9. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem 1995;270:29794-8.
10. Schweizer A, Valdenaire O, Nelbock P, Deuschle U, Dumas Milne Edwards JB, Stumpf JG, Loffler BM. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem J 1997;328:871-7.
11. Valdenaire O, Lepailleur-Enouf D, Egidy G, Thouard A, Barret A, Vranckx R, Tougard C, Michel JB. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur J Biochem 1999;264:341-9.
12. Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 1992;267:18797-804.
13. Arai H, Nakao K, Takaya K, Hosoda K, Ogawa Y, Nakanishi S, Imura H. The human endothelin-B receptor gene. Structural organization and chromosomal assignment. J Biol Chem 1993;268:3463-70.
14. Clozel M, Gray GA, Breu V, Loffler BM, Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992;186:867-73.
15. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14:385-99.
16. Elshourbagy NA, Korman DR, Wu HL, Sylvester DR, Lee JA, Nuthalaganti P, Bergsma DJ, Kumar CS, Nambi P. Molecular characterization and regulation of the human endothelin receptors. J Biol Chem 1993;268:3873-9.
17. Bagnato A, Venuti A, Di Castro V, Marcante ML. Identification of the ETA receptor subtype that mediates endothelin induced autocrine proliferation of normal human keratinocytes. Biochem Biophys Res Commun 1995;209:80-6.
18. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 1995;9:1196-204.
19. Granchi S, Vannelli GB, Vignozzi L, Crescioli C, Ferruzzi P, Mancina R, Vinci MC, Forti G, Filippi S, Luconi M, Ledda F, Maggi M. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod 2002;8:1053-64.
20. Fernandez-Durango R, Rollin R, Mediero A, Roldan-Pallares M, Garcia Feijo J, Garcia Sanchez J, Fernandez-Cruz A, Ripodas A. Localization of endothelin-1 mRNA expression and immunoreactivity in the anterior segment of human eye: expression of ETA and ETB receptors. Mol Vis 2003;9:103-9.
21. Kusuhara M, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S, Handa S, Nakamura Y. Abe K. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257-61.
22. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87:1867-71.
23. Economos K, MacDonald PC, Casey ML. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res 1992;52:554-7.
24. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995;1:1059-66.
25. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
26. Levin ER. Endothelins. N Engl J Med 1995;333:356-4.
27. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG. Expression of endothelin 1 and endothelin-A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999;59:720-7.
28. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G, Taylor I. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer 2001;85:1759-63.
29. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin-B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-8.
30. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999;96:11496-500.
31. Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosano L, Spinella F, Bagnato A. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002;103(Suppl 48):302-5.
32. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003;88:163-6.
33. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
34. Peduto Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells. Br J Cancer 2003;88:788-95.
35. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.
36. Green DR, Evan GI. A matter of life and death. Cancer Cells 2002;1:19-30.
37. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-14.
38. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
39. Wong DT, Todd R, Tsuji T, Donoff RB. Molecular biology of human oral cancer. Crit Rev Oral Biol Med 1996;7:319-28.
40. Dong G, Loukinova E, Chen Z, Gangi L, Chanturita TI, Liu ET, Van Waes C. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 2001;61:4797-808.
41. Wall NR, Shi Y. Small RNA: can RNA interference be exploited for therapy? Lancet 2003;362:1401-3; review.
42. Friedrich I, Shir A, Klein S, Levitzki A. RNA molecules as anti-cancer agents. Semin Cancer Biol 2004;14:223-30.
43. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994;269:18275-8.
44. Brown CD, Barnes K, Turner AJ. Anti-peptide antibodies specific to rat endothelin-converting enzyme-1 isoforms reveal isoform localisation and expression. FEBS Lett 1998;424:183-7.
45. Brown CD, Barnes K, Turner AJ. Functional significance of the isoforms of endothelin-converting enzyme-1. J Cardiovasc Pharmacol 2000;36(Suppl 1):S26-7.
46. Umekawa K, Hasegawa H, Tsutsumi Y, Sato K, Matsumura Y, Ohashi N. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin-converting enzyme. Jpn J Pharmacol 2000;84:7-15.
47. Ahmed SI, Thompson J, Coulson JM, Woll PJ. Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 2000;22:422-31.
48. Zhao YD, Springall DR, Hamid Q, Levene M, Polak JM. Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Pharmacol 1995;26(Suppl 3):S341-5.
49. Ali H, Dashwood M, Dawas K, Loizidou M, Savage F, Taylor I. Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol 2000;36(Suppl 1):S69-71.
50. Hachiya A, Kobayashi T, Takema Y, Imokawa G. Biochemical characterization of endothelin-converting enzyme-1α in cultured skin-derived cells and its postulated role in the stimulation of melanogenesis in human epidermis. J Biol Chem 2002;277:5395-403.
51. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-20; review.
52. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
53. Dawson LA, Maitland NJ, Turner AJ, Usmani BA. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer 2004;90:1577-82.
54. Berger Y, Dehmlow H, Blum-Kaelin D, Kitas EA, Löffler B-M, Aebi JD, Juillerat-Jeanneret L. Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem 2005;48:483-98.
55. Usmani BA, Harden B, Maitland NJ, Turner AJ. Differential expression of neutral endopeptidase-24-11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond) 2002;103(Suppl 48):3145-75.